Insider filing · GKOS
Tomas Navratil
CHIEF DEVELOPMENT OFFICER
profile →
Glaukos Corporation
GKOS · Healthcare · 31 filings in 24 months
ticker →
Tomas Navratil sold $2.5M of Glaukos (GKOS)
Executed Aug 28, disclosed Sep 1, 4 days later.
Value, as filed
$2.5M
13,734 sh across 2 lots
Executed
Aug 28
the trade date, as filed
Disclosed
Sep 1
4 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
TNTomas Navratil (CHIEF DEVELOPMENT OFFICER) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Glaukos Corporation (GKOS). The largest single filing was $2.5M of GKOS (13,734 sh across 2 lots, as filed), executed Aug 28.
The name
GKOSHealthcare · Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Tomas Navratil in GKOS
GKOSSALE
Glaukos Corporation
$201K1,537 sh × $130.68
Exec Jun 16
Filed Jun 18 · 5:30 PM ET GKOSSALE Glaukos Corporation $144K
1,237 sh × $116.72
Exec Apr 10
Filed Apr 14 · 5:30 PM ET GKOSSALE Glaukos Corporation $454K
5,142 sh across 2 lots
Exec Sep 11 2025
Filed Sep 12 2025 · 5:30 PM ET GKOSSALE Glaukos Corporation $503K
3,416 sh × $147.14
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET